Marina has over four years of experience in exosome-based drug development. With an extensive knowledge base in drug development from the R&D level to phase II clinical trials in the company Nano24, covering the aspects of GMP manufacturing, bio-assays development, regulatory submissions, QA, and CMC aspects. Before joining NurExone, held a CMC director position in Nano24 and led the exosome-based therapy toward clinical trials approvals.
Marina did her Ph.D. from the Tel Aviv University in Neuroscience in therapeutic efficiency evaluation of drug antagonists and agonists in in-vivo models of neuroinflammation.
